Impact Biomedical (IBO) Change in Receivables (2025 - 2026)

Impact Biomedical's (IBO) quarterly Change in Receivables came in at -$5000.0 in Q1 2026, up 50.0% on a QoQ basis from -$10000.0 in Q4 2025.

Impact Biomedical (IBO) Change in Receivables (2025 - 2026) Analysis & Trends

Impact Biomedical (IBO) has 2 years of Change in Receivables data on file, last reported at -$5000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Receivables (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	140.20 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	838.50 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-53.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	117.58 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	31.60 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	94.29 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	37.16 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Impact Biomedical	49.54 Mn	49.53 Mn	2,000.00	-

Download Data